Jump to top menu Jump to main menu Jump to content
AMIE beeldmerk
Core Facility

AMIE - Applied Molecular Imaging Erasmus MC

AMIE provides a platform for scientists who share an interest in state-of-the-art imaging technology and molecular imaging assays for studying biological systems. AMIE's unique strength lies in the fusion of superb expertise in imaging modes, availability of exclusive mouse models, and its strong links between basic, translational and patient-bound research


Methods / applications

Erasmus MC has been investing in imaging expertise and systems for quite some time and has built unique expertise in a number of areas. Various technologies (i.e. equipment as well as expertise) are put together in one new facility: Applied Molecular Imaging Erasmus. Combinations of imaging modalities can be applied to a single research question, or one experimental animal. From experience we know that a physical grouping of complementary techniques and expertise is a must to reach successful synergy. The new central imaging facility is largely housed in the new research unit in the Erasmus MC Experimental Animal Centre (EDC).

The research in the departments of Erasmus MC covers a wide range of topics; cancer research, microbiology/immunology, developmental biology and pharmacology.


Core Equipment:

  • IVIS – Optical Imaging
  • FMT2500 – Fluorescent Optical Imaging
  • Quantum FX – microCT
  • VECTor – SPECT/PET, microCT and Optical Imaging
  • Inveon – PET
  • Discovery MR901 – 7T MRI
  • NanoScan – SPECT, 1T MRI
  • Vevo3100 - Ultrasound (with LAZR-X photoacoustic addition)


Developmental/Other Equipment:

  • MSOT – Optoacoustic
  • Gammacounter for radioactive samples


Name: Prof. dr. ir. Marion de Jong
Radiology & Nuclear Medicine
Project Title:
Imaging and therapy using the same radiolabelled molecules

General description of research:
An important research line of the Deptartment of Nuclear Medicine is the development and application of radiolabeled peptides and other tracers for tumor imaging (detection, staging and monitoring using PET and SPECT) and radionuclide therapy. These compounds can therefore detect cancer and treat it. The approach showed most convincing results: in the preclinical setting excellent tumoricidal effects were found, whereas in the clinic in patients suffering from neuroendocrine tumors > 75% response rate is achieved. In order to be able to detect and treat more tumor types, we now focus on other peptide receptor systems as well (e.g. CCK, minigastrin, bombesin, GRP analogues). A short youtube video showing the concept of our work can be found at: https://www.youtube.com/watch?v=0YvG_MCXZsw



Access & costs

Access to and use of the AMIE instrumentation is allowed under supervision of the AMIE. Training is provided for those who plan to use the equipment independently.


Costs for equipment depends on user requirements. For more information contact the AMIE.


The AMIE provides full-service support on all equipment for imaging experiments with the option to obtain training for unsupported work.

All imaging modalities have isoflurane equipment for anesthesia.

Training & education


Users who would like to perform their own imaging research can be trained to use the equipment and make imaging protocols optimized for their research question, as well as training to analyze the data acquired.


The AMIE regularly organized the AMIE translational imaging workshop to educate participants ranging from clinicians to PhD students interested in imaging research on the many ways preclinical imaging works and how it benefits research.

News, events & publications


New multimodal phantom acquired:

Bioemtech fillable phantom for multimodal mouse imaging









Publications and theses


Nuclear Imaging Post-infarction Inflammation in Ischemic Cardiac Diseases - New Radiotracers for potential Clinical Applications. Krenning BJ, der Heiden KV, Duncker DJ, de Jong M, Bernsen MR.Curr Radiopharm. 2020 Oct 12.

Computed Tomography and Magnetic Resonance Imaging.
Bernsen MR, van Straten M, Kotek G, Warnert EAH, Haeck JC, Ruggiero A, Wielopolski PA, Krestin GP. Recent Results Cancer Res. 2020;216:31-110.

Imaging of inflammatory cellular protagonists in human atherosclerosis: a dual-isotope SPECT approach.
Barrett HE, Meester EJ, van Gaalen K, van der Heiden K, Krenning BJ, Beekman FJ, de Blois E, de Swart J, Verhagen HJ, Maina T, Nock BA, Norenberg JP, de Jong M, Gijsen FJH, Bernsen MR.Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2856-2865.

Imaging of atherosclerosis, targeting LFA-1 on inflammatory cells with 111In-DANBIRT. Meester EJ, Krenning BJ, de Blois RH, Norenberg JP, de Jong M, Bernsen MR, Van der Heiden K. 
J Nucl Cardiol. 2019 Oct;26(5):1697-1704.

Imaging heterogeneity of peptide delivery and binding in solid tumors using SPECT imaging and MRI. Haeck JC, Bol K, de Ridder CM, Brunel L, Fehrentz JA, Martinez J, van Weerden WM, Bernsen MR, de Jong M, Veenland JF. EJNMMI Res. 2016 Dec;6(1):3.

Nanoparticles and clinically applicable cell tracking. Bernsen MR, Guenoun J, van Tiel ST, Krestin GP. Br J Radiol. 2015 Oct;88(1054):20150375.

Magnetic Resonance Detection of CD34+ Cells from Umbilical Cord Blood Using a 19F Label. Duinhouwer LE, van Rossum BJ, van Tiel ST, van der Werf RM, Doeswijk GN, Haeck JC, Rombouts EW, Ter Borg MN, Kotek G, Braakman E, Cornelissen JJ, Bernsen MR. PLoS One. 2015 Sep 22;10(9):e0138572.

In vivo quantitative assessment of cell viability of gadolinium or iron-labeled cells using MRI and bioluminescence imaging. Guenoun J, Ruggiero A, Doeswijk G, Janssens RC, Koning GA, Kotek G, Krestin GP, Bernsen MR. Contrast Media Mol Imaging. 2013 Mar-Apr;8(2):165-74.

Evaluation of a Fluorescent and Radiolabeled Hybrid Somatostatin Analog In Vitro and in Mice Bearing H69 Neuroendocrine Xenografts. Santini C, Kuil J, Bunschoten A, Pool S, de Blois E, Ridwan Y, Essers J, Bernsen MR, van Leeuwen FW, de Jong M.J Nucl Med. 2016 Aug;57(8):1289-95.

In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography. van Deel E, Ridwan Y, van Vliet JN, Belenkov S, Essers J. J Vis Exp. 2016 Feb 16;(108):53603.



Preclinical SPECT-MRI; In vivo radiopeptide biodistribution studies. Joost Haeck, 2016

About us


Imaging at the AMIE

The AMIE is a facility where pre-clinical imaging equipment is centrally located and accessible to investigators with a research question which can be answered using the specialist equipment under guidance of imaging experts.


For inquiries please send an email to amie@erasmusmc.nl

Our team

Dr. Monique Bernsen – Head daily management

Dr. Jeroen Essers – Head innovation

Dr. Sandra van Tiel – Application specialist Nuclear Imaging & MRI

BSc. Yanto Ridwan – Application specialist Optical Imaging & CT

Dr. Joost Haeck – Application specialist MRI, Optoacoustic & Nuclear Imaging

Our expertise

AMIE is uniquely positioned within the Netherlands and relative to facilities in other countries worldwide. Not only does AMIE house an extensive array of imaging equipment with all modalities currently used for preclinical in vivo imaging, AMIE also has expert staff dedicated to the facility and is therefore able to continuously offer research support. Through close interaction with scientific experts and industry, AMIE fulfils a central role in the cycle of advancing imaging techniques, innovative research, and technology development, including hardware, software and wetware. That all equipment is only meters apart or even combined in a single platform is an immense benefit: study objects can be easily transferred between platforms giving investigators the opportunity to use several imaging modalities to gain extensive insight into their research question. This has already resulted in unique discoveries in various fields, e.g. stem-cell, cardiovascular and cancer research, which would not have been possible using single imaging modalities, and there remain many more applications which have yet to benefit from multi-modal experiments. Furthermore, imaging maximizes the information that can be gained from a given animal (refining), contributing to reduction of laboratory animal use.

The unique combination of extensive pre-clinical imaging equipment, cutting-edge technology, and dedicated in-house experts makes AMIE attractive to researchers both in NL and worldwide.


Erasmus MC departments using AMIE:

Experimental Cardiology

Molecular Genetics

Biomedical Engineering


Internal Medicine









Medical Oncology



Molecular Radiation Therapy

(Experimental) Surgery

Radiology & Nuclear Medicine


Dutch academic users:

AMC, Dept of Vascular Disease (V. de Waard et al)

LUMC, Dept of Radiology (Dr Eic Kaijzel et al, Dr. Fijs van Leeuwen et al.; Dr Louise van de Weerd)

Radboud UMC, Dept of Radiology and Nuclear Medicine (Dr Frank. Nijssen)

Radboud UMC, Radboud Institute for Molecular Life Sciences (Dr Mangala Srinivas)

TU Delft, Reactor Institute (Dr Antonia Denkova et al.; Dr. Marlies Goorden et al., Prof. Freek Beekman et al.Dr Dennis Schaart et al.)

TU Delft, 3ME (Dr Sharam JanBaz)

UVA, Biomedical Engineering and Physics department (Dr Gustav Strijkers)


Dutch non-academic users:

Milabs, Inc

Cenya BV

Quirem BV


International academic users:

Gent University (J. de Backer et al),

University of Pittsburgh (M. Weinberg, Z. Urban)

Athens (Demokritos): Theodosia Maina-Nock et al.

Montpellier University (Faculty of Pharmacy): Prof. Jean Martinez  et al.

Bad Berka, Kantonsspital, Prof. Richard Baum et al.


International non-academic users:

AAA (Novartis), Inc

Career opportunities

No positions currently available